Oncoinvent ASA
OSE:ONCIN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Oncoinvent ASA
OSE:ONCIN
|
NO |
|
Shilpa Medicare Ltd
NSE:SHILPAMED
|
IN |
|
SLC Agricola SA
BOVESPA:SLCE3
|
BR |
|
Dexco SA
BOVESPA:DXCO3
|
BR |
|
Webcentral Ltd
ASX:WCG
|
AU |
|
P
|
Pioneer Embroideries Ltd
NSE:PIONEEREMB
|
IN |
|
Modern Times Group MTG AB
STO:MTG B
|
SE |
|
3D Resources Ltd
ASX:DDD
|
AU |
Oncoinvent ASA
Oncoinvent ASA engages in the development of cancer treatment products. The company is headquartered in Oslo, Oslo and currently employs 34 full-time employees. The company went IPO on 2024-12-13. The firm is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The firm offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.
Oncoinvent ASA engages in the development of cancer treatment products. The company is headquartered in Oslo, Oslo and currently employs 34 full-time employees. The company went IPO on 2024-12-13. The firm is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The firm offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.
